Isomorphic Labs, the AI drug discovery company spun out of Alphabet's Google DeepMind, is in early talks to raise new funding at a valuation of at least $40 billion, according to Bloomberg. SiliconANGLE, citing the same report, says the valuation range could reach $50 billion, though the size of the round was not disclosed. The company's flagship IsoDDE platform targets drug design tasks such as binding pocket discovery; Isomorphic has claimed it outperforms AlphaFold on some of these tasks, figures that come from the company itself.